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The effect of drug therapy on the uptake of radioactive 
fluorine by osseous metastases 
RadioisotopiC techniques are potentially of considerable value to clinical pharmacology. 
Scintigrams and uptake studies are of particular interest, as they permit one to visualize 
lesions in many organs and to obtain simultaneously quantitative information on the degree of 
abnormality in the area of the lesion. Bone metastases take up increased amounts of 
fluorine-18; the present study was an investigation of the effect of therapy on this 
abnormal uptake. In eight patients with metastatic lesions to bone, chemotherapy or 
hormonal therapy produced temporary improvement in five, as ;udged by roentgenographic 
or clinical criteria, during the first four months after initiation of therapy. Serial 
scintigrams and quantitative uptake studies throughout this period showed that the 
abnormal ratio in fluorine uptake remained unchanged, despite the other evidence of 
temporary regression of metastases. Although the duration of time chosen for this study was 
consistent with that commonly used by physicians for evaluation of the effect of a given 
type of chemotherapy, our results suggest that such short-term studies must be interpreted 
cautiously. 
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Labeled compounds are available to 
permit scintigrams of most organs of the 
body. These radioisotopic techniques must 
now be studied to determine their useful-
ness to clinical pharmacology. The present 
preliminary report will indicate some of 
the difficulties associated with such studies. 
Roentgenography has already aided in 
the evaluation of certain forms of treat-
ment, and the use of scintigrams may well 
lend increased objectivity to evaluation of 
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therapy organs that cannot be well visual-
ized by roentgenographic techniques. The 
use of radioisotopic techniques may even 
offer advantages for the study of organs in 
which standard roentgen films demonstrate 
lesions. The former permit scintigrams and 
determinations of uptake simultaneously, a 
quantification that is not provided by 
roentgenographic studies, and in certain 
instances also offer increased sensitivity. 
Unfortunately, some of the basic principles 
of clinical pharmacology, e.g., serial studies 
of the same patient before and during 
therapy with "blind" evaluation of the re-
sults, have been absent from most studies 
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to date involving scintigrams. We have, 
therefore, attempted to apply these prin-
ciples to scintigrams and uptake determin-
ations obtained during the course of one 
type of therapy. 
The specific purpose of the present 
short-term study was to obtain preliminary 
information about the effect, if any, of drug 
therapy on the uptake of radioactive 
fluorine by bony metastases. The study 
was carried out during a relatively short 
period (four months) after initiation of 
therapy, as we were particularly interested 
in exploring the possibility that serial 
studies of bone with radioactive fluorine 
might give the physician early evidence 
about the effectiveness or lack of effective-
ness of any given drug chosen for the 
treatment of bony metastases. Bony metas-
tases have been demonstrated to take up 
increased amounts of several radionuclides, 
including radioactive fluorine. Scintigrams 
are often positive before roentgenographic 
demonstration of such lesions is possi-
ble.s, 11, 19 This increased sensitivity of 
scintigrams and uptake studies, as com-
pared to roentgen films, is not surprising. 
Although roentgenographic techniques are, 
of course, capable of diagnosing both 
osteoblastic and osteolytic lesions, experi-
ments based on decalcification of whole 
bones have suggested that 20 to 50 per 
cent of the calcium must be removed be-
fore the loss of calcium is visible roentgeno-
graphically in the first place.1 ,17 The fact 
that scintigrams have often been shown to 
reveal metastases before x-ray films do 
suggests the possibility that changes in 
osseous metastases, caused by therapy, 
might also be detectable by radioisotopic 
techniques before other evidence of the 
change becomes available. The size of the 
lesion is also of importance, as lesions of 
1 to 1.5 centimeters are usually the small-
est that may be well visualized by 
x-ray,2,4 but present scintigraphic tech-
niques are not superior to roentgeno-
graphic techniques in this regard. With 
radiOisotopic techniques the ratio of up-
take by the lesion to uptake by surround-
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ing tissue is also, of course, a highly im-
portant factor. 
Methods 
Selection of radioisotope. Fluorine-IS, 
introduced by Blau and Nagler, 3 was 
selected because of its short physical half-
life (nO minutes). The shorter physical 
half-life permits administration of a dose 
of 1 mc., with recording of a relatively 
high count rate shortly after administra-
tion of the radionuclide, while providing a 
relatively low radiation dose to the pa-
tient,l° The techniques used were the scin-
tigram (bone scan) and the quantitative 
uptake study.lO 
Selection of subjects. Eight adult pa-
tients were selected with the diagnoses, 
confirmed histologically in every instance, 
of carcinoma of the breast in 6, multiple 
myeloma in 1, and Hodgkin's disease in 1. 
Each patient also met all of the following 
criteria: (a) evidence that the primary 
disease had already metastasized; a scinti-
gram of at least one bone after administra-
tion of radioactive fluorine was positive at 
a time when the patient was receiving no 
chemotherapy or hormonal therapy for 
cancer; (b) no radiation therapy to the 
metastases under study had been given for 
at least 6 months prior to the beginning of 
the present study; (c) subsequent drug 
therapy was instituted within one week 
after the positive scintigram of bone had 
been obtained. In addition, 5 of the S pa-
tients had other evidence of bony metas-
tases, i.e., roentgenographic, clinical, or 
both. 
Technique of scintigrams and uptake 
studies. The preparation and use of fluo-
rine-IS have previously been described. 9 
The radionuclide was produced in a car-
rier-free state in the Ford Nuclear Reactor 
of the University of Michigan by bombard-
ment of enriched lithium-6 carbonate with 
thermal neutrons. After rapid separation 
of the radioactive fluorine in the form of 
sodium fluoride, I'> it was transported im-
"The cooperation of P. D. La Fleur is gratefully ac-
knowledged. 
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mediately to the University Medical Center 
and administered to the patients. 
The dose of 1 me. was administered in-
travenously in a volume of 5 to 10 ml. or 
orally in a volume of 25 to 50 ml. Approxi-
mately one hour after administration of 
the radioactive fluorine, the bony areas of 
interest and appropriate control areas were 
scanned with a photos canner'" employing 
a 3 inch crystal and a 19 hole focusing 
collimator. In accordance with standard 
practice, normal adjacent and contralateral 
areas of bone were used as controls. Of 
the total of 94 scintigrams performed in 
this study, all but 3 were performed by the 
same individual. t After completion of the 
scintigram the collimator was fixed in turn 
over each bony area of interest and appro-
priate control areas. The count rates ob-
tained over these areas were recorded with 
the aid of a scaler attached to the scanner. 
For example, if the area of interest was the 
pelvis, a series of fifteen-second counts was 
usually taken from each of 15 different 
areas, which followed the anatomical land-
marks of the pelvis in such a way as to 
map the entire pelvis. 
Interpretation of scintigrams, evaluation 
of the patient's clinical findings, and inter-
pretation of roentgen films were made at 
each visit by separate physicians, respec-
tively. One of us arranged all appointments 
for patients, ordered the necessary studies, 
and collected all reports without discussing 
the results with our co-workers. Another 
(H. D.) received the radioisotopic data, 
including the scintigrams, directly from 
the technician and recorded his opinion 
in writing before he was informed of the 
results of other studies. Roentgen films, 
taken by standard techniques, were evalu-
ated by a roentgenologist who had no 
knowledge of the other findings; in order 
to avoid introducing any characteristics of 
a "special study" into this evaluation, serial 
tomograms were not taken and only routine 
films were obtained serially. It is recog-
°Picker X-Ray Corporation, White Plains, N. Y. 
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nized that serial tomograms might have 
increased the frequency with which 
changes were detected roentgenograph-
ically. Clinical evaluation of each patient 
was carried out at the time of each visit 
by physicians who were not aware of the 
results of the radioisotopic studies or 
roentgenographic studies before they re-
corded their clinical impression in writing. 
Only after clinical, roentgenographic, and 
radioisotopic interpretations had been 
separately made and recorded, without 
reference one to the other, were all data 
collected and reviewed by the authors as a 
group. After recording his clinical impres-
sion, the physician supervising the patient's 
care had, of course, access to all data, but 
he did not discuss these with the various 
authors in any way that would vitiate the 
"blind" nature of the study. 
After initial selections of patients, drug 
therapy was chosen by the physicians 
responsible for the clinical care of each 
patient, usually in the chemotherapy or 
breast cancer clinics. '" In every instance 
the therapy chosen was that deemed best 
by the physician responsible for the pa-
tient's care and in no instance did the 
present study play any role in the decision 
to select a particular agent. Analgesics 
were given whenever indicated throughout 
the course of the study. 
In addition to the scintigram made with-
in one week prior to the beginning of drug 
therapy, each patient was again scanned at 
intervals after initiation of therapy. The 
usual intervals were 1, 2, and 4 weeks 
after initiation of therapy. Seven of 8 pa-
tients were also scanned at 8 weeks after 
the beginning of therapy, 6 at 12 weeks, 5 
at 16 weeks, 5 at 24 weeks, and 1 at 30 
weeks. In addition to the scintigram and 
uptake determinations, clinical evaluation, 
and roentgen studies that were made at 
each visit, determinations of serum cal-
cium, phosphorus, and alkaline phos-
phatase were regularly performed in the 
OWe are grateful to Drs. A. Burgess Vial and Court-
land M. Schmidt for their contribution to the care of 
these patients. 
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central biochemical laboratory of the hos-
pital. 
Results 
Five patients had clinical, roentgeno-
graphic, or combined evidence of improve-
ment during the course of therapy (Table 
I). In no instance was a clear change in 
the scintigram observed. 
A 
c 
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Figs. 1 and 2 exemplify the results ob-
tained in the entire series of patients. In 
the set of scintigrams shown in Fig. 1, 
there is no significant change in the "hot" 
area of increased uptake, relative to the 
uptake in surrounding normal areas. It 
should be stressed that the degree of ab-
normality of a scintigram after administra-
tion of radioactive fluorine must be judged 
Fig. 1. Scintigrams of the skull of Patient Y. D.: A, before treatment; B, 8 weeks after beginning of treatment; C, 16 weeks after beginning of treatment; and D, 24 weeks after beginning of treatment. In comparing the "hot" area in the parietal bone with the frontal bone, no significant changes in relative uptake are observable, despite over-all changes in the density of the scintigram. Scintigrams taken at 1, 2, 4, and 12 weeks in this patient 
were also similar to those shown. 
B 
D 
A 
c 
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with reference to the background counts 
obtained over normal areas. This criterion 
is much more reliable than the absolute 
density, for the latter may vary consider-
ably from one scintigram to another on 
the basis of technical scanning factors. In 
Fig. 2, questionable changes in the scinti-
grams were observed during the course of 
therapy. Changes of this degree were ob-
served in 7 of the 8 patients. The lack of 
a clear trend toward either an increase or 
decrease throughout the course of therapy 
in any patient and the lack of confirmatory 
changes in the uptake measurements ob-
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tained by point counting (see below) argue 
against the significance of these changes in 
the scintigram. 
The changes in uptake values, as ob-
tained by serial point counting, are sum-
marized in Table II. Therapy produced no 
significant trend toward increase or de-
crease in the ratio, counts per minute over 
lesion/counts per minute over control area. 
Here again, the absolute counts per minute 
obtained by point counting varied con-
siderably from week to week, but the ratio, 
counts per minute over lesion/counts per 
minute over control area, was less variable. 
B 
D 
Fig. 2. Scintigrams of the pelvis of Patient P. P.: A, before treatment; B, 8 weeks after 
beginning of treatment; C, 12 weeks after beginning of treatment; and D, 24 weeks after 
beginning of treatment. All four scintigrams show a high uptake on the right side of the 
pelvis. There is no discernible trend during therapy, as the difference between sides is greatest 
in B and least in C. Scintigrams taken at 1, 2, 4, and 16 weeks in this patient were not 
Significantly different from those shown here. 
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Table I. Chamcteristics of patients studied 
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Evidence of osseous metastases 
Patient Age Sex Diagnosis Clinical 
B. M. 54 F Carcinoma of breast Yes No Yes 
R. J. 52 F Carcinoma of breast Yes No Yes 
Y. D. 66 F Carcinoma of breast Yes Yes No 
p. p. 44 F Carcinoma of breast Yes No No 
H.L. 73 F Carcinoma of breast Yes Yes No 
J. M. 67 F Carcinoma of breast Yes Yes Yes 
G. E. 74 F Multiple myeloma Yes Yes Yes 
H. E. 33 M Hodgkin's disease Yes No No 
"This patient had metastases in spine and pelvis. Scan, x-ray, and clinical findings were all positive for each site. After 
treatment was then discontinued and drug therapy was reinstituted. Subsequent clinical and roentgenographic evidence of 
Table II. Uptake of radioactive fluorine by bony lesions (L) and control areas (C) as measured 
Patient B. M. 
Week of L l e I I L treatment RSI LSI LlC 6th TV 
0 1,500 1,400 1.07 3,500 
1 
2 2,776 2,448 1.13 6,828 
4 1,492 944 1.57 4,140 
8 4,728 3,204 1.48 4,100 
12 2,500 1,884 1.33 2,412 
16 2,796 2,192 1.27 3,468 
24 2,920 2,716 1.08 4,512 
30 
Abbreviations: RSI. right anterior superior spine of ilium 
LSI, left anterior superior spine of ilium 
TV, thoracic vertebra 
LV, lumbar vertebra 
"Studied at 6 weeks instead of 4 weeks. 
t Area irradiated during these weeks. 
Table II. Cont'd 
Patient H. L. 
Week of L e L 
treatment RSI LSI LlC LSI 
° 
1,052 828 1.27 2,400 
1 1,748 1,488 1.18 2,264 
2 844 1,108 0.76 2,552 
4 2,032 1,612 1.26 2,192 
8 1,048 1,148 0.92 1,340 
12 1,708 1,780 0.96 1,268 
16 1,896 1,808 1.05 1,180 
24 1,392 1,224 1.14 1,724 
30 1,350 
Abbreviations: RSI, right anterior superior spine of ilium 
LSI, left anterior superior spine of ilimn 
TV, thoracic vertebra 
LV, lumbar vertebra 
~Studied at 6 weeks instead of 4 weeks. 
t Area irradiated during these weeks. 
I 
Patient R. ]. 
e L 
I 
e I 2nd LV LlC 5th TV 7th TV 
2,700 1.30 2,200 1,800 
2,500 2,300 
4,844 1.41 1,304 1,276 
2,900 1.43 1,664'" 1,364'" 
3,444 1.19 2,136 1,740 
1,644 1.47 3,220 2,924 
2,364 1.54 
2,972 1.52 
RPAR. right parietal bone 
LP AR, left parietal bone 
FR, frontal bone. 
Patient J. M. 
C 
I 2nd
L 
LV I 
C 
RSI Lie Sacrum 
1,976 1.22 
3,064 0.74 
2,768 0.92 
1,860 1.18 
1,116 1.20 
1,068 1.19 
988 1.20 
1,040 1.66 
1,300 0.98 
RP AR, right parietal bone 
LPAR, left parietal bone 
FR, frontal bone 
4,580 3,808 
6,168 5,428 
6,016+ 5,680 
7,004t 6,476 
3,492 2,960 
2,884 2,312 
2,832 2,108 
4,592 3,816 
4,100 3,500 
LlC 
1.22 
1.09 
1.02 
1.22'" 
1.23 
1.10 
I LlC 
1.20 
1.14 
1.06 
1.09 
1.18 
1.25 
1.34 
1.20 
1.17 
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Therapy 
Cyclophosphamide 
Cyclophosphamide 
Diethylstilbestrol 
Fluoxymesterone 
Diethylstilbestrol 
Cyclophosphamide" 
Cyclophosphamide 
Nitrogen mustard 
Duration of 
study (weeks) 
24 
12 
24 
24 
24 
30 
8 
4 
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Significant posttreatment changes 
Scan X-ray Clinical findings 
None None Improvement at 6 weeks 
Relapse at 24 weeks 
None None None 
None Improvement at 24 weeks None 
None None None 
None None Improvement at 2 weeks 
None Improvement at 24 weeks Improvement at 12 weeks 
None None Improvement at 8 weeks 
None None None 
completion of one week of drug treatment this was omitted for 4 weeks while x-ray treahn€nt was given to the spfne. X-ray 
improvement was noted in both spinal and pelvic lesions. 
by point counting (all values except ratios refer to counts pel' minute) 
Patient Y. D. Patient P. P. 
L C L C L C 
RSI LSI LlC LPAR FR LlC RSI LSI LlC 
2,944 2,388 l.23 2,872 1,360 2.11 1,336 1,168 1.14 
2,064 1,712 1.21 3,484 1,872 1.86 1,768 1,560 1.13 
3,004 2,200 1.37 2.748 1,848 1.49 1,684 1,372 1.22 
3,272 2,580 1.27 2,144 1,240 1.73 1,364 1,264 1.08 
3,776 2,840 1.33 3,156 2,104 1.50 2,064 1,544 1.34 
2,616 1.952 1.34 2,264 1,320 1.72 1,404 1,456 0.97 
2,524 2,260 1.12 1.904 1,140 1.67 872 620 1.41 
2,284 2,040 LI2 2,136 1,276 1.67 1,598 1,536 1.04 
Patient C. E. Patient H, E. 
L C L C 
I 
L C 
RSI LSI LlC FR RPAR LlC 8th TV 3rd LV LlC 
1,456 1,724 0.84 1,788 1,336 1.34 4,200 3,400 1.24 
2,928 2,512 1.17 2,172 1,348 1.61 3,000 2,864 1.05 
2,840 2,532 1.12 
2,808 2,524 1.11 1,988 1,288 1.54 3,136 2,680 1.17 
940 752 1.25 616 572 1.09 
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Table III shows the serial values of 
serum calcium, phosphorus, and alkaline 
phosphatase concentrations in these pa-
tients. No significant trend was apparent 
during the course of therapy except for 
changes in serum phosphorus concentra-
tion. The latter fell in four patients (Y. D., 
P. P., H. L., and G. E.) but the presence 
or absence of this fall did not correlate 
significantly with the presence or absence 
of improvement of the patient. 
Discussion 
The primary purpose of this study was to 
apply the techniques of nuclear medicine 
to clinical pharmacology. Although certain 
tentative conclusions may be drawn from 
the present study, a realistic evaluation of 
the difficulties encountered is also neces-
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sary. Moreover, among the variety of 
labeled compounds that have been de-
veloped to permit scintigraphic demonstra-
tion of lesions in different organs, the 
mechanisms of uptake differ greatly. There-
fore, the short-term and long-term effects 
of drug therapy on scintigrams and uptake 
values will require separate investigation 
for each organ to determine the proper 
place of radioisotopic studies in clinical 
pharmacology. 
In the specific model we chose, uptake 
studies by point counting were of con-
siderable help in supplementing the scinti-
grams, espeCially in the original classifica-
tion of scans as positive or negative. The 
primary criterion of positivity of a scan 
was increased denSity over one or more 
areas as compared to background. This 
Table III. Serial values of serum calCium, phosphorus, and alkaline phosphatase 
Week of treatment 
Patient 0 1 2 8 12 16 24 30 
Calcium (mg. %) 
B. M. 10.8 12.0 11.2 11.3 9.1 12.0 11.7 11.3 
R. J. 9.3 9.4 9.3 9.8" 8.8 10.2 
Y. D. 9.9 10.1 8.5 9.7 9.1 10.3 9.5 9.7 
p. p. 10.0 9.6 10.3 10.6 9.9 9.4 10.0 
H.L. 10.1 9.6 8.2 10.1 10.7 9.4 9.6 9.4 
J. M. 10.3 10.0 10.1 10.4 9.9 10.3 9.8 10.2 
G. E. 10.6 9.9 8.2 
H. E. 9.6 9.2 9.4 
Phosphorus (mg. %) 
B. M. 2.8 3.3 3.4 3.2 2.7 3.1 3.5 3.0 
R. J. 4.7 4.8 3.6 4.4" 4.5 4.5 
Y. D. 3.8 2.7 2.8 2.7 2.7 2.9 2.3 2.7 
p. p. 4.4 3.3 4.2 4.2 3.6 2.8 3.0 3.2 
H. L. 4.0 3.8 3.0 3.4 2.2 2.3 2.2 2.3 
J. M. 3.5 3.7 4.2 3.3 3.6 3.8 3.3 3.7 
G. E. 4.7 2.9 2.5 
H. E. 4.2 3.3 4.7 
Alkaline phosphatase (King-Armstrong units) 
B. M. 80.0 76.0 79.0 55.0 22.0 22.0 60.0 
R. J. 6.5 8.4 7.8 8.1 " 9.3 8.6 
Y. D. 7.8 9.6 9.2 8.8 9.1 10.1 8.3 10.7 
p. p. 9.7 6.3 8.1 8.5 8.1 5.1 7.6 7.4 
H. L. 14.0 16.0 9.5 11.8 11.3 14.9 12.0 11.0 
J. M. 41.0 25.0 23.7 22.0 24.0 23.0 24.3 25.0 
G. E. 6.4 7.6 9.4 
H. E. 15.0 20.8 12.3 13.0 
"Studied at 6 weeks instead of 4. 
Volume 8 
Number 5 
was confirmed, in every instance but one, 
by point counts that showed the suspected 
lesion to have at least 20 per cent more 
activity than the control area. However, 
point counting presents technical difficul-
ties in accurate localization of the probe 
over the various areas of interest, par-
ticularly when the counting is done on a 
routine basis. Therefore, we are justified in 
concluding only that our present tech-
niques suggested the absence of any large 
change in scintigrams or uptake values 
during a period when 5 of the 8 patients 
studied showed other evidence consistent 
with improvement under therapy. 
Although a recognized difficulty in 
evaluating the significance of the present 
radioisotopic study is the fact that the 
other methods of evaluating improvement 
under therapy may themselves have been 
misleading, the possibility that the im-
provement noted may have been com-
pletely illusory seems remote. In patients 
Y. D. and J. M. improvement in bony 
metastases was eventually shown roent-
genographically. The clinical improvement 
in patients B. M. and G. E. was also 
sufficiently definite to suggest favorable 
effect of therapy on bony metastases. Pa-
tient B. M. had metastases, demonstrated 
by scintigram, in the spine and pelvis, 
while patient G. E. had definite roentgeno-
graphic and scintigraphic evidence of 
widespread lesions of multiple myeloma in 
the pelvis and skull. Both B. M. and G. E. 
had difficulty in walking; B. M. had back 
pain while G. E. had diffuse bone pain. 
Following therapy, B. M. reported a re-
markable decrease in back pain, G. E. 
noted disappearance of her bone pain, and 
both had improvement in their ability to 
walk. In addition, a striking decrease in 
the hepatomegaly of B. M. was observed. 
At present it is uncertain whether the 
increased deposition of radioactive fluorine 
around bony lesions is primarily related to 
increased local blood flow accompanying 
these lesions, increased availability of 
denuded surface of bone for exchange, or 
some other factor. It would, therefore, be 
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difficult to predict a priori what changes 
one might expect if therapy caused "heal-
ing" of metastases, i.e., one might expect 
the fluorine uptake to increase or decrease 
during such "healing." But in any event, 
significant changes in fluorine uptake were 
not observed under the conditions of this 
study. 
Reported experience with the uptake of 
other radionuclides by bony metastases and 
the changes induced by therapy should be 
noted. Several investigators14• 16, 20 have 
described changes in the uptake of stron-
tium-85 by bony metastases after therapy, 
as determined by point counting or scan-
ning. Both increased and decreased uptake 
have heen claimed as a result of therapy. 
None of these reports described more than 
3 patients. Moreover, none of the patients 
reported can be compared strictly with 
those studied in the present series, for the 
patients reported by the aforementioned 
authors differed from our patients in one 
or more of the follOWing respects: no men-
tion was made of "blind" evaluations, con-
clusions were based primarily on changes 
in lesions for which x-ray therapy or 
surgery (castration) was also used, or 
the patients were scanned only at inter-
vals of 5 to 6 months or longer. Several 
authors 5 , 7, 1G, 18 have reported changes in 
uptake of ca1cium-47 after therapy of bony 
metastases, as detennined by point count-
ing or scanning. Here again, both increased 
and decreased uptake after therapy have 
been claimed and evaluations were ap-
parently not "blind." Reports usually con-
cerned 1 to 3 patients. Most of the patients 
were not comparable to ours in that sur-
gical removal of endocrine organs or x-ray 
therapy played a major role in the treat-
ment of the former. Moreover, in certain 
instances evaluation was based on com-
parison of a treated lesion and an un-
treated lesion, rather than serial studies of 
the same lesion before and after treatment. 
But Corey7 did report serial studies of re-
tention of strontium-85 by a patient with 
two vertebral metastases from breast car-
cinoma. Initially both sites showed high 
656 Kampffmeyer et al. 
uptake of strontium. Seventy-five days after 
the beginning of testosterone therapy the 
retention of strontium by one metastatic 
site had fallen to the same level as in the 
normal spine, while the other site con-
tinued to show high retention. In summary, 
studies with radioactive calcium and 
strontium, as reported thus far, do not 
clearly show that these radio nuclides would 
behave differently from radioactive fluorine 
in a controlled study of the short-term 
effect of drug therapy on bony metastases, 
although the restrictions on measurement 
imposed by the short physical half-life of 
fluorine-I8 and the difference between the 
kinetics of fluorine-I8 and the kinetics of 
calcium and strontium make it unwise to 
compare fluorine studies closely with cal-
cium-strontium studies. 
Extension of our conclusions to radiation 
therapy does not seem justified. Significant 
reversal of a positive bone scan in a pa-
tient with reticulum cell sarcoma has been 
reported during a 3 months' period of ob-
servation after radiation therapy.ll Green-
berg and co-workers13 have reported a 
difference between an untreated lesion of 
reticulum cell sarcoma and a radiation-
treated lesion when both were studied 
serially in the same patient with calcium-
47. Finston, Woodard, and Laughlin12 have 
shown in dogs that irradiation affects the 
retention of calcium-47 and strontium-85 
even in bone that was normal before ir-
radiation. 
Our results thus far suggest that radio-
isotopic studies of bone will continue to 
show definite abnormalities at the site of 
metastases, even when current forms of 
drug therapy have produced temporary 
improvement, as judged by other criteria. 
However, the short-term nature of the 
study and the preliminary nature of the 
conclusions drawn from it should be 
stressed. As noted above, the other criteria 
of temporary improvement are not always 
reliable indicators of the true state of bony 
lesions, and our present conclusions may 
reflect more the difficulties in interpreta-
tion posed by current fluorine uptake tech-
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niques than a true lack of correlation be-
tween the effect of therapy and the turn-
over of the radionuclide in bone. N ever-
theless, our results thus far suggest that 
the effects of cancer chemotherapeutic 
agents should probably not be determined 
on a short-term basis and that some of the 
commonly accepted short-term criteria for 
judging the success of cancer chemother-
apy may be misleading. 
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